Johnson & Johnson temporarily halts Covid-19 vaccine output: report
NYSE - LSE
| RIO | -0.92% | 73.06 | $ | |
| CMSC | -0.21% | 23.43 | $ | |
| BCC | -1.66% | 73.05 | $ | |
| SCS | -0.56% | 16.14 | $ | |
| CMSD | -0.3% | 23.25 | $ | |
| NGG | -0.66% | 75.41 | $ | |
| GSK | -0.33% | 48.41 | $ | |
| JRI | 0.29% | 13.79 | $ | |
| BTI | -1.81% | 57.01 | $ | |
| BCE | 1.4% | 23.55 | $ | |
| BP | -3.91% | 35.83 | $ | |
| RBGPF | 0% | 78.35 | $ | |
| RYCEF | -0.34% | 14.62 | $ | |
| AZN | 0.17% | 90.18 | $ | |
| RELX | -0.55% | 40.32 | $ | |
| VOD | -1.31% | 12.47 | $ |
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.
The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.
J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.
The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.
J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.
"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.
J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.
But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.
Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.
(O.Zhukova--DTZ)
